Monday, April 13, 2009

Glenmark completes phase I trial of GRC 10693 in Europe

Glenmark Pharmaceuticals Limited (GPL) has successfully completed phase I trials of its candidate for neuropathic pain, osteoarthritis and other inflammatory pain disorders - GRC 10693 in Europe.

the details can be read here.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)